OZURDEX®—for ophthalmic intravitreal injection
The intravitreal injection procedure should be carried out under controlled aseptic conditions. For complete dosage and administration directions, refer to section 2.2 (Administration) of the full Prescribing Information of OZURDEX®. Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis without delay.
OZURDEX® is indicated for the treatment of DME.
- The visual acuity improvement from baseline increases during a treatment cycle, peaks at approximately 3 months posttreatment, and diminishes thereafter1
- Reinjection with OZURDEX® is recommended at the physician’s discretion whenever residual macular edema is present1